PDSB PDS Biotechnology Corporation

5.44
-0.18  -3%
Previous Close 5.62
Open 5.72
52 Week Low 0.664
52 Week High 7.2967
Market Cap $121,103,207
Shares 22,261,619
Float 19,076,877
Enterprise Value $96,880,990
Volume 712,867
Av. Daily Volume 1,978,554
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
PDS0101 and chemoradiotherapy
Cervical cancer
Phase 2a
Phase 2a
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
PDS0101 VERSATILE-002
Head and neck cancer
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Versamune
COVID-19 Vaccine
Phase 1/2
Phase 1/2
Phase 1/2 trial to be initiated in Brazil 2Q / 3Q 2021.
PDS0101 and Bintrafusp alfa (M7824)/ NHS-IL12
Human papillomavirus (HPV) associated cancers
Phase 2
Phase 2
Phase 2 achieved its preliminary objective response - February 3, 2021.
PDS0101
Cervical intraepithelial neoplasia (CIN)
Phase 1
Phase 1
Phase 2 trial will not be initiated - noted October 1, 2019.

Latest News

  1. FLORHAM PARK, N.J., March 18, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced its financial results for the year ended December 31, 2020 and provided a business update.

    Recent Business Highlights:

    • Achieved preliminary efficacy benchmark in the Phase 2 combination trial of PDS0101 led by the National Cancer Institute.
    • Initiated VERSATILE-002, a Phase 2 trial of lead investigational drug candidate PDS0101, in combination with standard of care KEYTRUDA® for first-line treatment of patients with metastatic or recurrent…

    FLORHAM PARK, N.J., March 18, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced its financial results for the year ended December 31, 2020 and provided a business update.

    Recent Business Highlights:

    • Achieved preliminary efficacy benchmark in the Phase 2 combination trial of PDS0101 led by the National Cancer Institute.
    • Initiated VERSATILE-002, a Phase 2 trial of lead investigational drug candidate PDS0101, in combination with standard of care KEYTRUDA® for first-line treatment of patients with metastatic or recurrent HPV-positive head and neck cancer.
    • Phase 2 trial of lead investigational drug candidate PDS0101, in combination with standard of care chemoradiotherapy for patients with advanced cervical cancer was initiated by the University of Texas MD Anderson Cancer Center.
    • Expanded consortium for development of PDS0203, a novel, Versamune®-based second-generation COVID-19 vaccine to include Blanver Farmoquímica in addition to Farmacore.
    • Received award commitment of up to $60 million from Brazil's Ministry of Science, Technology and Innovation (MCTI) to fund clinical development and commercialization of PDS0203.
    • Strengthened leadership team with the appointment of Seth Van Voorhees as Chief Financial Officer and addition of preeminent oncologist Otis Brawley, M.D. to the board of directors.

    "Despite the challenges of 2020, the PDS Biotech team remained focused on the advancement of our Versamune®-based drug pipeline," commented Dr. Frank Bedu-Addo, President and Chief Executive Officer of PDS Biotech. "Through that commitment and the strength of our partnerships with leading institutions in the fields of immuno-oncology and infectious disease, we made significant strides in solidifying the safety profile and establishing the efficacy of our Versamune® platform and products as we continue to progress our portfolio towards commercialization."

    Full Year 2020 Financial Results

    For the year ended December 31, 2020, the net loss was approximately $14.8 million, or $0.89 per basic share and diluted share, compared to a net loss of approximately $7.0 million, or $1.44 per basic share and diluted share for the year ended December 31, 2019.

    For the year ended December 31, 2020, research and development expenses increased to $7.9 million compared to $6.1 million during the prior year. The increase was primarily the result of increased expenses related to manufacturing and personnel costs for the ongoing clinical studies.

    For the year ended December 31, 2020, general and administrative expenses decreased to $7.0 million compared to $11.0 million during 2019. The $4.0 million decrease was due to decreases in personnel costs of $0.4 million, non-cash stock-based compensation of $2.4 million, D&O insurance costs of $0.5 million, legal fees of $0.5 million and professional fees of $0.2 million.

    Total operating expenses for 2020 were $14.9 million, a decrease of approximately 29% compared to $21.0 million during the prior year.

    The company's cash balance as of December 31, 2020 was $28.8 million.

    Conference Call and Webcast

    The conference call is scheduled to begin at 8:00 am ET on Thursday, March 18, 2021. Participants should dial 877-407-3088 (United States) or 201-389-0927 (International) and mention PDS Biotech. Participants can also access the conference call via webcast on the investor relations page of the Company's corporate website (link).

    The event will be archived in the investor relations section of PDS Biotech's website for 6 months. In addition, a telephonic replay of the call will be available for 6 months. The replay can be accessed by dialing 877-660-6853 (United States) or 201-612-7415 (International) with confirmation code 13716518.

    About PDS Biotechnology

    PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

    Forward Looking Statements

    This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the "Company") and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company's management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend,"  "forecast," "guidance", "outlook" and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company's ability to protect its intellectual property rights; the Company's anticipated capital requirements, including the Company's anticipated cash runway and the Company's current expectations regarding its plans for future equity financings; the Company's dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company's operations or require the Company to relinquish rights to the Company's technologies or product candidates; the Company's limited operating history in the Company's current line of business, which makes it difficult to evaluate the Company's prospects, the Company's business plan or the likelihood of the Company's successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune® based products; the future success of such trials; the successful implementation of the Company's research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune® based products and the Company's interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company's product candidates; the acceptance by the market of the Company's product candidates, if approved; the timing of and the Company's ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company's product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company's control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company's annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

    Media & Investor Relations Contact:

    Deanne Randolph

    PDS Biotechnology

    Phone: +1 (908) 517-3613

    Email:

    Jacob Goldberger

    CG Capital

    Phone: +1 (404) 736-3841

    Email:



    PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

    Condensed Consolidated Balance Sheets

     December 31,

    2020
     December 31,

    2019
    ASSETS   
    Current assets:   
    Cash and cash equivalents$28,839,565  $12,161,739 
    Prepaid expenses and other 1,497,665   2,308,462 
    Total current assets 30,337,230   14,470,201 
          
    Property and equipment, net 5,443   21,051 
    Operating lease right-to-use asset 547,706    
          
    Total assets$30,890,379  $14,491,252 
          
    LIABILITIES AND STOCKHOLDERS' EQUITY     
    Current liabilities:     
    Accounts payable$1,415,224  $1,197,720 
    Accrued expenses 1,735,322   1,097,640 
    Restructuring reserve    498,185 
    Operating lease obligation - short term 119,904    
    Total current liabilities 3,270,450   2,793,545 
          
    Noncurrent liability:     
    Operating lease obligation - long term 490,353    




    Total liabilities
    $3,760,803  $2,793,545 
          
          
    STOCKHOLDERS' EQUITY     
    Common stock, $0.00033 par value, 75,000,000 shares authorized at December 31, 2020 and

       December 31, 2019, 22,261,619 shares and 5,281,237 shares issued and outstanding at

       December 31, 2020 and December 31, 2019, respectively
     7,346   1,742 
    Additional paid-in capital 70,907,315   40,633,670 
    Accumulated deficit (43,785,085)  (28,937,705)
    Total stockholders' equity 27,129,576   11,697,707 
          
    Total liabilities and stockholders' equity$30,890,379  $14,491,252 





    PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES

    Condensed Consolidated Statements of Operations and Comprehensive Loss

     Year Ended December 31,
     2020  2019 
    Operating expenses:   
    Research and development expenses$7,924,450  $6,099,580 
    General and administrative expenses 6,962,328   10,981,765 
    Impairment expense IPRD    2,974,000 
    Lease termination costs    979,273 
    Depreciation 15,608    
          
    Total operating expenses 14,902,386   21,034,618 
          
    Loss from operations (14,902,386)  (21,034,618)
          
    Other income (expense):     
    Gain on bargain purchase upon merger    13,334,568 
    Interest income 55,006   353,490 
    Interest expense    (33,559)
          
    Loss before income taxes (14,847,380)

      (7,380,119)
          
    Income taxes (benefit)    (381,513)
    Net loss and comprehensive loss$(14,847,380) $(6,998,606)
          
    Per share information:     
    Net loss per share, basic and diluted$(0.89) $(1.44)
          
    Weighted average common shares outstanding basic and diluted 16,745,044   4,868,079 



    Primary Logo

    View Full Article Hide Full Article
  2. Florham Park, New Jersey--(Newsfile Corp. - March 17, 2021) - PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced that Dr. Frank Bedu-Addo, CEO of PDS Biotech, will present the company's immunotherapy platform, ongoing phase 2 clinical programs, product pipeline and upcoming milestones virtually at the Benzinga Biotech Small Cap Conference on Wednesday, March 24 at 10:05 am ET. In addition, Dr. Bedu-Addo will participate in the "Cancer Immunotherapies: Fighting Cancer with the power of the Immune System" panel immediately following his presentation at 10:25am…

    Florham Park, New Jersey--(Newsfile Corp. - March 17, 2021) - PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced that Dr. Frank Bedu-Addo, CEO of PDS Biotech, will present the company's immunotherapy platform, ongoing phase 2 clinical programs, product pipeline and upcoming milestones virtually at the Benzinga Biotech Small Cap Conference on Wednesday, March 24 at 10:05 am ET. In addition, Dr. Bedu-Addo will participate in the "Cancer Immunotherapies: Fighting Cancer with the power of the Immune System" panel immediately following his presentation at 10:25am ET on Wednesday, March 24.

    Individuals interested in attending the event can register online here: https://www.benzinga.com/events/small-cap/biotech/. A replay of the Company's presentation will be available online in the investor relations section of the Company's website for 90 days following the event.

    About PDS Biotechnology

    PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

    Media & Investor Relations Contact:

    Deanne Randolph
    PDS Biotech
    Phone: +1 (908) 517-3613
    Email:

    Jacob Goldberger
    CG Capital
    Phone: +1 (404) 736-3841
    Email:

    ​To view the source version of this press release, please visit https://www.newsfilecorp.com/release/77530

    View Full Article Hide Full Article
  3. FLORHAM PARK, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on PDS Biotech's proprietary Versamune® T-cell activating technology, today announced that its COVID-19 vaccine consortium consisting of PDS Biotech, Farmacore Biotechnology and Blanver Farmoquímica, has received a commitment from the Secretary for Research and Scientific Training of the MCTI to fund up to approximately US$60 million to support the clinical development and commercialization of a novel, Versamune®-based, second generation COVID-19 vaccine in Brazil.

    MCTI intends to start making the funds available to prepare to perform…

    FLORHAM PARK, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on PDS Biotech's proprietary Versamune® T-cell activating technology, today announced that its COVID-19 vaccine consortium consisting of PDS Biotech, Farmacore Biotechnology and Blanver Farmoquímica, has received a commitment from the Secretary for Research and Scientific Training of the MCTI to fund up to approximately US$60 million to support the clinical development and commercialization of a novel, Versamune®-based, second generation COVID-19 vaccine in Brazil.

    MCTI intends to start making the funds available to prepare to perform a combined Phase 1/2 clinical trial, upon authorization by the Brazilian regulatory agency, Agência Nacional de Vigilância Sanitária (Anvisa) to initiate the proposed Versamune®-based COVID-19 vaccine clinical program in Brazil.

    The pre-IMPD package for the Phase 1/2 trial is currently under review by Anvisa and the trial is anticipated to begin by Q2/3 2021. The majority of the capital provided by MCTI will fund the manufacturing process scale up, production and the Phase 3 trial, pending the results of the Phase 1/2 trial. The consortium members will work under a mutually agreed work plan to guide the vaccine efficiently through development in compliance with regulatory standards. The consortium anticipates working to initiate manufacturing scale up activities in the second quarter.

    This award is based on the preclinical studies of the Versamune®-based COVID-19 vaccine. The vaccine combines PDS Biotech's Versamune® T-cell activating platform technology with a SARS-CoV-2 recombinant protein derived from the spike (S) protein. Notably, the protein in this fully synthetic vaccine includes conserved and non-mutating regions of the virus. The vaccine has demonstrated strong potential in preclinical studies to efficiently promote the induction of killer (CD8+) and helper (CD4+) T-cells that recognize and induce immune responses against such non-mutating regions of the virus. The protein also includes regions of the spike protein that result in the induction of neutralizing antibodies.

    The Phase 1 and 2 trials, which will be run together, are anticipated to enroll approximately 360 patients and will assess the safety and efficacy of the vaccine as well as both the antibody and killer T-cell responses induced by the vaccine to the novel coronavirus. The clinical trials are planned to be conducted in Brazil.

    "PDS Biotech and Farmacore Biotechnology have taken the important step of advancing our Versamune®-based COVID-19 vaccine into the clinic," said Dr. Frank Bedu-Addo, Chief Executive Officer of PDS Biotech." The preclinical results demonstrate the vaccine's potential to induce a broad range of robust anti SARS-CoV-2 immune responses. The rapidly increasing number of SARS-CoV-2 mutations highlights the need for novel, second generation vaccines capable of generating both killer and helper T-cells that can recognize and attack conserved and non-mutating regions of the virus. We applaud Farmacore Biotechnology and Blanver Farmoquímica for reaching this important milestone and look forward to the results of the planned human clinical trials and hopefully a rapid advancement towards commercialization of the product. These clinical trials will also advance our understanding of the potential for novel Versamune®-based vaccines to provide long-term protection against infection with viruses with pandemic potential such as SARS-CoV-2."

    "We are excited to continue advancing the program with PDS Biotech, and we are thrilled to have had the continued support of the Brazilian government as we finalize clinical study protocols with Anvisa for human testing of the novel vaccine combining the Versamune® T-cell activating technology with the SARS-CoV-2 recombinant protein antigen. We are proud to advance this promising medicine in Brazil in the fight against this global pandemic," said Helena Faccioli, CEO of Farmacore Biotechnology.

    As the license holder of PDS0203 in Latin America, Farmacore Biotechnology will continue to lead the regulatory and clinical trial efforts in Brazil and has selected a top clinical research organization, to conduct clinical trials in Brazil. PDS Biotech will continue to contribute scientific expertise and operational support and oversee scale up of the manufacturing process. Blanver Farmoquímica will manufacture, promote, distribute, and commercialize the Versamune®-based COVID-19 vaccine in Latin America.

    All funding is contingent on the availability of financial resources within the MCTI, and The Secretary for Research and Scientific Training of the MCTI has committed to making every effort to finance all clinical and development stages of the program.

    About PDS Biotechnology

    PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

    About Farmacore Biotechnology

    Farmacore Biotechnology is a biotechnology company, founded in 2005, focusing on R&D of innovative immunobiological products for use in the human and veterinary health sectors. It is a technology-based company that conducts research and development of biotechnological products and processes for the human and veterinary sectors. It develops innovative biotechnological and immunobiological products and adds value to them in all stages of development, from project design to biomolecule production www.farmacore.com.br.

    About Blanver Farmoquímica

    Blanver Farmoquímica e Farmacêutica S.A. is a Brazilian company, founded in 1984, focused on R&D, manufacture and sale of innovative medicines and active pharmaceutical ingredients. The company plays in the segments of HIV, Hepatitis, Oncology and Hematology, providing high quality products for expanding the population's access to medicines through partnerships with the Ministry of Health and official laboratories. Blanver Farmoquímica is committed in always looking for innovations that will improve people's health and quality of life.

    About PDS0203

    PDS0203 is an investigational vaccine designed for the prevention of COVID-19 being jointly developed for Latin America by a consortium that includes PDS Biotech, Farmacore Biotechnology and Blanver Farmoquímica. The vaccine combines the utility of PDS Biotech's Versamune® platform with a recombinant native Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) protein recognizable by our immune system (antigen). The Versamune® platform, due to its unique ability to induce both antibody and polyfunctional CD8+ killer and CD4+ helper T-cell responses is being utilized to develop a next generation vaccine that may more effectively prevent COVID-19.

    Forward Looking Statements

    This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the "Company") and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company's management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," "forecast." "guidance", "outlook" and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company's ability to protect its intellectual property rights; the Company's anticipated capital requirements, including the Company's anticipated cash runway and the Company's current expectations regarding its plans for future equity financings; the Company's dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company's operations or require the Company to relinquish rights to the Company's technologies or product candidates; the Company's limited operating history in the Company's current line of business, which makes it difficult to evaluate the Company's prospects, the Company's business plan or the likelihood of the Company's successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101 and PDS0203 ; the future success of such trials; the successful implementation of the Company's research and development programs and collaborations, including any collaboration studies concerning PDS0101 and PDS0203 and the Company's interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company's product candidates; the acceptance by the market of the Company's product candidates, if approved; the timing of and the Company's ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company's product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company's control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to the COVID-19 pandemic. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company's annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

    Media & Investor Relations Contact:

    Deanne Randolph

    PDS Biotech

    Phone: +1 (908) 517-3613

    Email:

    Jacob Goldberger

    CG Capital

    Phone: +1 (404) 736-3841

    Email:



    Primary Logo

    View Full Article Hide Full Article
  4. FLORHAM PARK, N.J., March 08, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced that the Company will release financial results for the three- and twelve-month periods ended December 31, 2020 on Thursday, March 18, 2021, before the market opens. Following the release, management will host a conference call to review the financial results and provide a business update.

    The conference call is scheduled to begin at 8:00 am ET on Thursday, March 18, 2021. Participants should dial 877-407-3088 (United States) or 201-389-0927 (International…

    FLORHAM PARK, N.J., March 08, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced that the Company will release financial results for the three- and twelve-month periods ended December 31, 2020 on Thursday, March 18, 2021, before the market opens. Following the release, management will host a conference call to review the financial results and provide a business update.

    The conference call is scheduled to begin at 8:00 am ET on Thursday, March 18, 2021. Participants should dial 877-407-3088 (United States) or 201-389-0927 (International) and mention PDS Biotechnology. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.pdsbiotech.com.

    After the live webcast, the event will be archived on PDS Biotech's website for 6 months. In addition, a telephonic replay of the call will be available for 6 months. The replay can be accessed by dialing 877-660-6853 (United States) or 201-612-7415 (International) with confirmation code 13716518.

    About PDS Biotechnology

    PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

    Media & Investor Relations Contact:

    Deanne Randolph

    PDS Biotech

    Phone: +1 (908) 517-3613

    Email:

    Jacob Goldberger

    CG Capital

    Phone: +1 (404) 736-3841

    Email:



    Primary Logo

    View Full Article Hide Full Article
  5. FLORHAM PARK, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced that Frank Bedu-Addo, CEO of PDS Biotech, will present at the H.C. Wainwright Global Life Sciences Conference being held from March 9-10, and at the 31st Annual Oppenheimer Healthcare Conference being held from March 16-18. Both conferences are being hosted virtually.

    H.C. Wainwright & Co. Global Life Sciences Conference
    Date: Presentation Available On-Demand March 9-10, 2021
    Registration: Click Here

    31st Annual Oppenheimer Healthcare Conference

    FLORHAM PARK, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced that Frank Bedu-Addo, CEO of PDS Biotech, will present at the H.C. Wainwright Global Life Sciences Conference being held from March 9-10, and at the 31st Annual Oppenheimer Healthcare Conference being held from March 16-18. Both conferences are being hosted virtually.

    H.C. Wainwright & Co. Global Life Sciences Conference

    Date: Presentation Available On-Demand March 9-10, 2021

    Registration: Click Here

    31st Annual Oppenheimer Healthcare Conference

    Date: March 16, 2021 at 1:10 PM Eastern Time

    Registration: Click Here

    Replays of the presentations will be available online in the investor relations section of the Company's website for 90 days following the events.

    About PDS Biotechnology

    PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

    Forward Looking Statements

    This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the "Company") and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company's management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," "forecast." "guidance", "outlook" and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company's ability to protect its intellectual property rights; the Company's anticipated capital requirements, including the Company's anticipated cash runway and the Company's current expectations regarding its plans for future equity financings; the Company's dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company's operations or require the Company to relinquish rights to the Company's technologies or product candidates; the Company's limited operating history in the Company's current line of business, which makes it difficult to evaluate the Company's prospects, the Company's business plan or the likelihood of the Company's successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for its lead asset PDS0101; the future success of such trials; the successful implementation of the Company's research and development programs and collaborations, including any collaboration studies concerning PDS0101 and the Company's interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company's product candidates; the acceptance by the market of the Company's product candidates, if approved; the timing of and the Company's ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company's product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company's control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company's annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

    Media & Investor Relations Contact:

    Deanne Randolph

    PDS Biotech

    Phone: +1 (908) 517-3613

    Email:  

    Jacob Goldberger

    CG Capital

    Phone: +1 (404) 736-3841

    Email:  



    Primary Logo

    View Full Article Hide Full Article
View All PDS Biotechnology Corporation News